Claims for Patent: 8,491,893

Summary for Patent: 8,491,893

Title:	Oncofetal antigen/immature laminin receptor antibodies for diagnostic and clinical applications
Abstract:	The present invention relates to antibodies against Oncofetal Antigen/immature Laminin receptor protein (OFA/iLRP) that can be used singly or in conjunction to detect or treat OFA/iLRP-related diseases. More specifically, the antibodies can be used for several purposes including: (i) detecting and measuring OFA/iLRP in different biofluids; and (ii) using OFA/iLRP with an antibody directed against the monomeric form and its associated diseases.
Inventor(s):	Olle; Eric W. (Unicoi, TN)
Assignee:	Quantum Immunologics, Inc. (Tampa, FL)
Application Number:	12/732,880
Patent Claims:	1. An isolated antibody or a fragment thereof that specifically binds to an epitope of the oncofetal antigen/immature laminin receptor protein (OFA/iLRP), wherein the epitope is or lies within the amino acid sequence of VTDPRADHQPLTE (SEQ ID NO.:3), YRDPEEIEKEEQ (SEQ ID NO.:4), or YRDPEEIEKEEQC (SEQ ID NO.:9). 2. The isolated antibody of claim 1, wherein the epitope is or lies within the amino acid sequence of VTDPRADHQPLTE (SEQ ID NO.:3), or YRDPEEIEKEEQ (SEQ ID NO.:4). 3. The isolated antibody of claim 1, wherein the antibody is a monoclonal antibody. 4. The isolated antibody of claim 3, wherein the epitope is or lies within the amino acid sequence of YRDPEEIEKEEQC (SEQ ID NO.:9). 5. A pharmaceutical composition comprising the antibody of claim 1. 6. The composition of claim 5, wherein the antibody is a monoclonal antibody. 7. The composition of claim 5, further comprising a pharmaceutically acceptable carrier. 8. The isolated antibody of claim 1, which is conjugated to a detectable label. 9. The isolated antibody of claim 8, wherein the detectable label is selected from the group consisting of radioisotopes, fluorescent labels, and enzyme-substrate labels. 10. A pharmaceutical composition of claim 7, wherein the pharmaceutically acceptable carrier comprises a stabilizing agent, a wetting agent, an emulsifying agent, a salt, an encapsulating agent, a buffer, a skin penetration enhancing agent, or a combination of two or more thereof. 11. The pharmaceutical composition of claim 7, wherein the carrier comprises a sterile diluent, an antioxidant, a chelating agent, a buffer, an agent for the adjustment of tonicity, a pH adjusting agent, or a combination of two or more thereof. 12. The pharmaceutical composition of claim 7, wherein the carrier comprises physiological saline, sterile water, Cremophor EL, or phosphate buffered saline. 13. The pharmaceutical composition of claim 7, wherein the carrier comprises an agent that delays absorption, a preservative, or both. 14. The pharmaceutical composition of claim 5, which is formulated in a controlled release formulation. 15. The pharmaceutical composition of claim 14, wherein the antibody is contained in a microencapsulated delivery system. 16. The pharmaceutical composition of claim 14, wherein the antibody is encapsulated in a liposome. 17. The pharmaceutical composition of claim 4, which is formulated for oral administration. 18. The pharmaceutical composition of claim 4, which is formulated for parenteral administration. 19. The pharmaceutical composition of claim 4, which is formulated as a dosage unit form.

Details for Patent 8,491,893

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2029-03-26